^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Gastric Adenocarcinoma

Related cancers:
CPEB1 underexpression
Gastric Adenocarcinoma
5-fluorouracil
Sensitive
:
C3
J Gastrointest Oncol - 2 weeks - (New C3)
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab
Sensitive
:
A2
HER-2 overexpression
Gastric Adenocarcinoma
trastuzumab
Sensitive
:
A2
HER-2 overexpression
Gastric Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
PD-L1 expression
Gastric Adenocarcinoma
nivolumab
Sensitive
:
A2
HER-2 overexpression
Gastric Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive
:
A2
MET expression
Gastric Adenocarcinoma
AMG 102
Resistant
:
B
MET amplification
Gastric Adenocarcinoma
AMG 102
Resistant
:
B
PD-L1 underexpression
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
B
HER-2 positive
Gastric Adenocarcinoma
pembrolizumab + margetuximab
Sensitive
:
C2
CLDN18.2 expression
Gastric Adenocarcinoma
IMAB362
Sensitive
:
C2
HER-2 amplification
Gastric Adenocarcinoma
trastuzumab + avelumab
Sensitive
:
C2
MET amplification
Gastric Adenocarcinoma
crizotinib
Sensitive
:
C3
PD-L1 expression
Gastric Adenocarcinoma
pembrolizumab + margetuximab
Sensitive
:
C3
ATM mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive
:
C3
ATR mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive
:
C3
ATRX mutation
Gastric Adenocarcinoma
Immunotherapy
Sensitive
:
C3
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab + surufatinib
Sensitive
:
C3
HER-2 amplification
Gastric Adenocarcinoma
HER2 inhibitor
Resistant
:
C3
Chr amplification(11)(q13)
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
MDM2 amplification
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
MDM4 amplification
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
CDKN2A deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
CDKN2B deletion
Gastric Adenocarcinoma
Immunotherapy
Resistant
:
C3
PD-L1 expression
Gastric Adenocarcinoma
PD-L1 inhibitor
Sensitive
:
C3
MSI-H/dMMR
Gastric Adenocarcinoma
atezolizumab
Sensitive
:
C3
HER-2 negative
Gastric Adenocarcinoma
cisplatin + paclitaxel + capecitabine
Sensitive
:
C3
MET amplification
Gastric Adenocarcinoma
RG3638
Sensitive
:
C4
HER-2 1899‐1G>A
Gastric Adenocarcinoma
trastuzumab
Resistant
:
C4
FGFR3 amplification
Gastric Adenocarcinoma
pazopanib
Sensitive
:
C4
FGFR2 amplification
Gastric Adenocarcinoma
futibatinib
Sensitive
:
D
FGFR2 amplification
Gastric Adenocarcinoma
nintedanib
Sensitive
:
D